Which has preferable earnings and valuation, NMRA or SVRA?

Savara is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A Savara N/A N/A -$118.84M -$0.56 N/A

Is NMRA or SVRA more profitable?

Savara's return on equity of -87.19% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -181.70% -119.15% Savara N/A -87.19% -66.42%

Do analysts prefer CALT or NMRA?

Neumora Therapeutics has a consensus price target of $6.86, indicating a potential upside of 310.61%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Neumora Therapeutics 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has higher earnings & valuation, NMRA or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A

Is NMRA or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -38.92% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -181.70% -119.15% Corvus Pharmaceuticals N/A -38.92% -35.75%

Which has stronger valuation and earnings, CGEM or NMRA?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A

Is CGEM or NMRA more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Neumora Therapeutics N/A -181.70% -119.15%

Neumora Therapeutics (NMRA) Competitors

$1.67 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.68 +0.02 (+0.90%)

As of 07/2/2026 07:00 PM Eastern

Compare

NMRA vs. SVRA, CALT, COLL, CRVS, and CGEM

Should you buy Neumora Therapeutics stock or one of its competitors? MarketBeat compares Neumora Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neumora Therapeutics include Savara (SVRA), Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Corvus Pharmaceuticals (CRVS), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

How does Neumora Therapeutics compare to Savara?

Neumora Therapeutics (NASDAQ:NMRA) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

In the previous week, Savara had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 1 mentions for Savara and 0 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.00 equaled Savara'saverage media sentiment score.

Company	Overall Sentiment
Neumora Therapeutics	Neutral
Savara	Neutral

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Savara is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Neumora Therapeutics has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market. Comparatively, Savara has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Savara's return on equity of -87.19% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Savara	N/A	-87.19%	-66.42%

Neumora Therapeutics currently has a consensus price target of $6.86, suggesting a potential upside of 310.61%. Savara has a consensus price target of $10.14, suggesting a potential upside of 63.07%. Given Neumora Therapeutics' higher possible upside, research analysts clearly believe Neumora Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Savara beats Neumora Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Neumora Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Neumora Therapeutics' return on equity of -181.70% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Neumora Therapeutics	N/A	-181.70%	-119.15%

In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Neumora Therapeutics'average media sentiment score.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Neumora Therapeutics	Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Neumora Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Neumora Therapeutics has a consensus price target of $6.86, indicating a potential upside of 310.61%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, meaning that its share price is 174% more volatile than the broader market.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Neumora Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 14 factors compared between the two stocks.

How does Neumora Therapeutics compare to Collegium Pharmaceutical?

Neumora Therapeutics (NASDAQ:NMRA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Neumora Therapeutics currently has a consensus target price of $6.86, suggesting a potential upside of 310.61%. Collegium Pharmaceutical has a consensus target price of $57.50, suggesting a potential upside of 55.28%. Given Neumora Therapeutics' higher probable upside, research analysts plainly believe Neumora Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17

Collegium Pharmaceutical has a net margin of 9.41% compared to Neumora Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 1 mentions for Collegium Pharmaceutical and 0 mentions for Neumora Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.50 beat Neumora Therapeutics' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Overall Sentiment
Neumora Therapeutics	Neutral
Collegium Pharmaceutical	Very Positive

Collegium Pharmaceutical has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Collegium Pharmaceutical	$796.33M	1.51	$62.87M	$2.04	18.15

47.7% of Neumora Therapeutics shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Neumora Therapeutics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Neumora Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to Corvus Pharmaceuticals?

Neumora Therapeutics (NASDAQ:NMRA) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Neumora Therapeutics has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

In the previous week, Neumora Therapeutics' average media sentiment score of 0.00 equaled Corvus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Neumora Therapeutics	Neutral
Corvus Pharmaceuticals	Neutral

Corvus Pharmaceuticals' return on equity of -38.92% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Neumora Therapeutics presently has a consensus price target of $6.86, suggesting a potential upside of 310.61%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 118.87%. Given Neumora Therapeutics' higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Neumora Therapeutics beats Corvus Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Neumora Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cullinan Therapeutics' average media sentiment score of 0.00 equaled Neumora Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cullinan Therapeutics	Neutral
Neumora Therapeutics	Neutral

Cullinan Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 81.51%. Neumora Therapeutics has a consensus target price of $6.86, suggesting a potential upside of 310.61%. Given Neumora Therapeutics' higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Cullinan Therapeutics' return on equity of -51.45% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Neumora Therapeutics	N/A	-181.70%	-119.15%

Summary

Neumora Therapeutics beats Cullinan Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMRA vs. The Competition

Export

Metric	Neumora Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$309.42M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.26	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	2.69	8.66	10.96	6.46
Net Income	-$236.93M	$23.81M	$3.57B	$337.01M
7 Day Performance	1.83%	3.39%	2.12%	1.69%
1 Month Performance	2.45%	10.81%	5.25%	3.81%
1 Year Performance	105.92%	62.61%	33.29%	23.90%

Neumora Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMRA Neumora Therapeutics	3.7502 of 5 stars	$1.67 flat	$6.86 +310.6%	+105.9%	$309.42M	N/A	N/A	108	Gap Down
SVRA Savara	1.7115 of 5 stars	$6.03 +2.2%	$10.14 +68.2%	+191.3%	$1.21B	N/A	N/A	20	News Coverage
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
COLL Collegium Pharmaceutical	3.4356 of 5 stars	$35.98 -1.7%	$57.50 +59.8%	+21.9%	$1.19B	$780.57M	17.64	210	Positive News
CRVS Corvus Pharmaceuticals	2.152 of 5 stars	$14.48 +7.3%	$33.33 +130.2%	+287.0%	$1.13B	N/A	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMRA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neumora Therapeutics (NMRA) Competitors

NMRA vs. SVRA, CALT, COLL, CRVS, and CGEM

How does Neumora Therapeutics compare to Savara?

Summary

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Neumora Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Neumora Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Neumora Therapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neumora Therapeutics (NMRA) Competitors

NMRA vs. SVRA, CALT, COLL, CRVS, and CGEM

How does Neumora Therapeutics compare to Savara?

Does the media refer more to NMRA or SVRA?

Do insiders & institutionals have more ownership in NMRA or SVRA?

Which has preferable earnings and valuation, NMRA or SVRA?

Which has more risk and volatility, NMRA or SVRA?

Is NMRA or SVRA more profitable?

Do analysts prefer NMRA or SVRA?

Summary

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Is CALT or NMRA more profitable?

Does the media prefer CALT or NMRA?

Which has preferable valuation and earnings, CALT or NMRA?

Do analysts prefer CALT or NMRA?

Which has more risk & volatility, CALT or NMRA?

Do institutionals and insiders have more ownership in CALT or NMRA?

Summary

How does Neumora Therapeutics compare to Collegium Pharmaceutical?

Do analysts recommend NMRA or COLL?

Is NMRA or COLL more profitable?

Does the media favor NMRA or COLL?

Which has better earnings and valuation, NMRA or COLL?

Do institutionals & insiders have more ownership in NMRA or COLL?

Which has more volatility and risk, NMRA or COLL?

Summary

How does Neumora Therapeutics compare to Corvus Pharmaceuticals?

Which has more risk & volatility, NMRA or CRVS?

Which has higher earnings & valuation, NMRA or CRVS?

Does the media refer more to NMRA or CRVS?

Is NMRA or CRVS more profitable?

Do analysts recommend NMRA or CRVS?

Do insiders & institutionals have more ownership in NMRA or CRVS?

Summary

How does Neumora Therapeutics compare to Cullinan Therapeutics?

Which has stronger valuation and earnings, CGEM or NMRA?

Which has more risk & volatility, CGEM or NMRA?

Do insiders and institutionals hold more shares of CGEM or NMRA?

Does the media prefer CGEM or NMRA?

Do analysts rate CGEM or NMRA?

Is CGEM or NMRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools